Products for Research Use Only

Brepocitinib

CAT: 0804-HY-112708-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112708-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1].
CAS Number
1883299-62-4
Product Name Alternative
PF-06700841
UNSPSC
12352005
Hazard Statement
H303, H315, H319, H335
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/PF-06700841.html
Purity
99.97
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C([C@H]1C(F)(F)C1)N2C3CN(C4=NC(NC5=CN(C)N=C5)=NC=C4)CC2CC3
Molecular Formula
C18H21F2N7O
Molecular Weight
389.40
Precautions
H303, H315, H319, H335
References & Citations
[1]Fensome A, et al. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S) -2,2-Difluorocyclopropyl) ((1 R,5 S) -3- (2- ((1-methyl-1 H-pyrazol-4-yl) amino) pyrimidin-4-yl) -3,8-diazabicyclo[3.2.1]octan-8-yl) methanone (PF-06700841) . J Med Chem. 2018 Oct 11;61 (19) :8597-8612.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
JAK1; JAK2; JAK3
Citation 01
Heliyon. 2023 Jan 13;9 (1) :e12958.|J Exp Clin Cancer Res. 2024 May 30;43 (1) :152.|Inflamm Bowel Dis. 2021 Oct 18;27 (10) :1674-1683.